Summary
Cardinal Health, Inc. (CAH) filed an 8-K on July 5, 2006, reporting significant changes to executive roles and compensation, as well as a material definitive agreement. Specifically, David L. Schlotterbeck has been appointed Chief Executive Officer of Pharmaceutical and Medical Products, expanding his leadership to encompass additional key segments of the company. This expanded role comes with a substantial increase in his annual base salary, reflecting the added responsibilities. In addition to leadership changes, the filing also details the authorization for President and CEO R. Kerry Clark to use corporate aircraft for personal travel, with accompanying tax reimbursements. These executive-level adjustments and benefits are important for investors to understand regarding management structure and incentives. The report also indicates the furnishing of a press release from July 5, 2006, as an exhibit.
Key Highlights
- 1David L. Schlotterbeck appointed Chief Executive Officer of Pharmaceutical and Medical Products, expanding his leadership scope.
- 2Mr. Schlotterbeck's annual base salary increased from $580,000 to $725,000 in connection with his expanded role.
- 3Mr. Schlotterbeck's target annual bonus remains at 100% of his new annual base salary.
- 4R. Kerry Clark, President and CEO, authorized to use corporate aircraft for personal travel.
- 5The company will provide tax reimbursement to Mr. Clark for income attributed to his personal use of corporate aircraft.
- 6The filing is linked to a press release issued by the company on July 5, 2006.